Live Analyst Rating Changes 23245 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Robbie Marcus
JPM

Robbie Marcus

J.P. Morgan
Wall Street Analyst
★★★★★
#285
on 13Foresight · ranked by our own returns
74%
Success Rate
+9.9%
Average Return
42 of 57 calls profitable · +2.6% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 74% of Robbie Marcus's ratings turned a profit when each position was held for 1 year — averaging +9.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

42 Buy 36 Hold 7 Sell
Robbie's Stock Coverage 38 ratings · 2026-08-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
KMTS
Kestra Medical Technologies Ltd.
 Aug 10, 2026 BUY Strong Buy
+0.9% avg upside
9 analysts
$30.00
5.84% Upside
 -1.9% ·
RXST
RxSight
 Aug 06, 2026 SELL Hold
+28.9% avg upside
13 analysts
$6.00
8.75% Downside
 -14.5% ·
BAX
Baxter International
 Aug 06, 2026 HOLD Buy
+21.2% avg upside
23 analysts
$26.00
6.40% Downside
 +1.8% ·
PODD
Insulet
 Aug 05, 2026 HOLD Strong Buy
+50.6% avg upside
32 analysts
$152.00
6.34% Upside
 +8.8% ·
DXCM
Dexcom
 Aug 04, 2026 HOLD Strong Buy
+19.0% avg upside
32 analysts
$82.00
6.50% Downside
 +2.9% ·
IART
Integra Lifesciences
 Aug 04, 2026 SELL Buy
+150.1% avg upside
21 analysts
$17.00
0.37% Downside
 +4.5% ·
INSP
Inspire Medical Systems
 Aug 04, 2026 HOLD Buy
+42.9% avg upside
21 analysts
$60.00
0.43% Upside
 -9.1% ·
SYK
Stryker
 Aug 04, 2026 BUY Strong Buy
+6.1% avg upside
37 analysts
$350.00
1.20% Upside
 +2.9% ·
MMSI
Merit Medical Systems
 Aug 04, 2026 BUY Strong Buy
+8.9% avg upside
15 analysts
$95.00
5.87% Upside
 +3.8% ·
BSX
Boston Scientific
 Jul 30, 2026 BUY Strong Buy
+32.8% avg upside
38 analysts
$56.00
11.07% Upside
 +7.2% ·
GEHC
GE Healthcare Technologies Inc
 Jul 30, 2026 HOLD Strong Buy
+13.0% avg upside
22 analysts
$70.00
3.98% Downside
 +3.4% ·
CNMD
Conmed
 Jul 30, 2026 HOLD Hold
+31.5% avg upside
12 analysts
$45.00
9.06% Downside
 +4.6% ·
EW
Edwards Lifesciences
 Jul 28, 2026 BUY Strong Buy
+7.8% avg upside
34 analysts
$105.00
14.00% Upside
 +11.4% ·
ISRG
Intuitive Surgical
 Jul 21, 2026 BUY Strong Buy
+19.9% avg upside
36 analysts
$450.00
14.32% Upside
 +14.6% ·
ABT
Abbott Laboratories
 Jul 17, 2026 BUY Strong Buy
+5.2% avg upside
36 analysts
$120.00
10.50% Upside
 +7.9% ·
COO
Cooper Co
 Jun 05, 2026 HOLD Buy
+75.0% avg upside
21 analysts
$71.00
6.99% Downside
 +10.2% ·
MDT
Medtronic
 Jun 05, 2026 HOLD Buy
+6.9% avg upside
38 analysts
$86.00
3.85% Downside
 +10.6% ·
MOBI
Mobia Medical, Inc.
 Jun 02, 2026 BUY Strong Buy
+60.6% avg upside
4 analysts
$15.00
17.89% Upside
 -11.2% ·
CVRX
CVRx
 May 12, 2026 SELL Buy
+190.5% avg upside
9 analysts
$6.00
153.14% Upside
 +54.6% ·
ZBH
Zimmer Biomet Holdings
 Apr 29, 2026 HOLD Buy
+17.5% avg upside
38 analysts
$95.00
2.83% Downside
 +22.0% ·
HTFL
HeartFlow, Inc.
 Mar 25, 2026 BUY Strong Buy
+23.4% avg upside
9 analysts
$35.00
19.27% Upside
 +4.7% ·
PEN
Penumbra
 Dec 18, 2025 BUY Buy
+1.2% avg upside
23 analysts
$370.00
13.60% Upside
 +3.6% ·
CBLL
Ceribell, Inc.
 Nov 05, 2025 BUY Strong Buy
+20.7% avg upside
8 analysts
$17.00
11.90% Downside
 +85.1% ·
BLCO
Bausch + Lomb Corporation
 Oct 30, 2025 HOLD Buy
+18.5% avg upside
19 analysts
$16.00
4.91% Downside
 +11.2% ·
ENOV
Enovis
 Aug 08, 2025 HOLD Strong Buy
+172.7% avg upside
39 analysts
$33.00
36.21% Upside
 -6.4% ·
INGN
Inogen
 Aug 08, 2025 SELL Buy
+317.4% avg upside
7 analysts
$7.00
16.19% Upside
 +6.6% ·
BDX
Becton Dickinson
 Aug 07, 2025 HOLD Buy
+8.3% avg upside
25 analysts
$190.00
5.71% Upside
 +22.8% ·
BVS
Bioventus
 May 06, 2025 HOLD Strong Buy
-2.9% avg upside
8 analysts
$7.00
49.81% Downside
 +76.1% ·
ATRC
Atricure
 Feb 11, 2025 BUY Strong Buy
+8.1% avg upside
13 analysts
$51.00
22.39% Upside
 -20.7% ·
NPCE
NeuroPace
 Dec 17, 2024 BUY Strong Buy
+20.8% avg upside
13 analysts
$14.00
5.89% Downside
 +35.6% ·
TMCI
Treace Medical Concepts
 May 08, 2024 HOLD Hold
+21.8% avg upside
8 analysts
$8.00
71.41% Upside
 +80.8% ·
UTRS
Minerva Surgical
 Sep 06, 2022 SELL Hold
+7999900.0% avg upside
4 analysts
 — · ·
AFIB
Acutus Medical
 Nov 18, 2021 SELL Sell
+494900.1% avg upside
5 analysts
 — · ·
SDCCQ
SmileDirectClub
 Aug 10, 2021 SELL Sell
+449649900.0% avg upside
10 analysts
$6.00
5999899.99% Upside
 · ·
GKOS
Glaukos
 May 06, 2021 SELL Strong Buy
-8.3% avg upside
21 analysts
$85.00
53.05% Downside
 +50.0% ·
IRTC
Irhythm Technologies
 Apr 12, 2021 HOLD Strong Buy
+28.9% avg upside
20 analysts
$95.00
23.82% Downside
 +84.1% ·
TMDX
TransMedics Group
 May 28, 2019 BUY Strong Buy
+16.6% avg upside
15 analysts
$34.00
61.52% Downside
 -54.1% ·
PENN
PENN Entertainment
 Jun 08, 2018 BUY Strong Buy
+58.3% avg upside
32 analysts
$40.00
112.25% Upside
 -39.1% ·
🔒 33 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Robbie Marcus — Frequently Asked Questions
How accurate are Robbie Marcus's stock ratings?
Based on the calls 13Foresight could measure, about 74% of Robbie's ratings were profitable over a one-year hold, with an average return of +9.6% per rating, or +2.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Robbie ranked on 13Foresight?
Robbie Marcus is currently ranked #285 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Robbie cover?
Robbie most recently has ratings on KMTS, RXST, BAX, PODD, DXCM, IART, INSP, SYK, MMSI, BSX, GEHC, CNMD and 26 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.